Risk Factors for Relapse of Hyperglycemia after Laparoscopic Roux-en-Y Gastric Bypass in T2DM Obese Patients: a 5-Year Follow-Up of 24 Cases.
Adult
Aged
Body Mass Index
C-Peptide
/ blood
Chronic Disease
Diabetes Mellitus, Type 2
/ blood
Female
Follow-Up Studies
Gastric Bypass
/ methods
Glycated Hemoglobin
/ analysis
Humans
Hyperglycemia
/ etiology
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Laparoscopy
Life Style
Male
Middle Aged
Obesity
/ blood
Obesity, Morbid
/ blood
Patient Compliance
Preoperative Period
Recurrence
Retrospective Studies
Risk Factors
Treatment Outcome
Weight Loss
LRYGB
Obesity
Recurrence of T2DM
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
16
1
2019
medline:
11
2
2020
entrez:
16
1
2019
Statut:
ppublish
Résumé
To explore the risk factors for relapse of hyperglycemia in obese patients with type II diabetes mellitus (T2DM) who received laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery. A retrospective analysis was performed on all obese patients with T2DM who underwent a LRYGB during the period 2011-2013. Demographics, preoperative body mass index (BMI), preoperative glycated hemoglobin A1c (HbA1c), adherence to lifestyle intervention, preoperative medication of insulin, and the time interval between surgery and diagnosis of T2DM were investigated and compared. A total of 24 patients were included in our study. The median age was 45.5 years, the median BMI was 29.9 kg/m The preoperative HbA1c level and C-peptide level at surgery have an important significance in predicting the relapse of hyperglycemia after LRYGB surgery; lifestyle intervention is crucial for these patients.
Identifiants
pubmed: 30645722
doi: 10.1007/s11695-018-03656-9
pii: 10.1007/s11695-018-03656-9
doi:
Substances chimiques
C-Peptide
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164-1168Références
Baena-Díez JM, Peñafiel J, Subirana I, Ramos R, Elosua R, Marín-Ibañez A, Guembe MJ, Rigo F, Tormo-Díaz MJ, Moreno-Iribas C, Cabré JJ, Segura A, García-Lareo M, Gómez de la Cámara A, Lapetra J, Quesada M, Marrugat J, Medrano MJ, Berjón J, Frontera G, Gavrila D, Barricarte A, Basora J, García JM, Pavone NC, Lora-Pablos D, Mayoral E, Franch J, Mata M, Castell C, Frances A, Grau M, FRESCO Investigators. Risk of cause-specific death in individuals with diabetes: a competing risks analysis [J]. Diabetes Care, 2016, 39(11): 1987, 1995.
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract. 2018;138:271–81.
doi: 10.1016/j.diabres.2018.02.023
pubmed: 29496507
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial [J]. Lancet. 2015;386(9997):964–73.
doi: 10.1016/S0140-6736(15)00075-6
pubmed: 26369473
Aminian A, Brethauer SA, Andalib A, Punchai S, Mackey J, Rodriguez J, Rogula T, Kroh M, Schauer PR Can sleeve gastrectomy “cure” diabetes? Long-term metabolic effects of sleeve gastrectomy in patients with type 2 diabetes [J]. Ann Surg, 2016, 264(4): 674, 681.
Brethauer SA, Aminian A, Romero-Talamã s H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus [J]. Ann Surg, 2013, 258(4): 636–637.
Buse JB, Caprio S, Cefalu WT, Ceriello A, del Prato S, Inzucchi SE, McLaughlin S, Phillips GL, Robertson RP, Rubino F, Kahn R, Kirkman MS How do we define cure of diabetes? [J]. Diabetes Care, 2009, 32(11): 2133–2135.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus [J]. Ann Surg, 2003, 238(4): 467–484.
Rubino F, Kaplan LM, Schauer PR, et al. The diabetes surgery summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus [J]. Ann Surg. 2010;251(3):399–405.
doi: 10.1097/SLA.0b013e3181be34e7
pubmed: 19934752
Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes [J]. Arquivos Brasileiros De Endocrinologia E Metabologia. 2011;5(3):e171–89.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes [J]. N Engl J Med. 2012;366(17):1567–76.
doi: 10.1056/NEJMoa1200225
pubmed: 22449319
pmcid: 3372918
Pournaras DJ, Aasheim ET, Søvik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012 Jan;99(1):100–3.
doi: 10.1002/bjs.7704
pubmed: 22021090
Digiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up [J]. Surg Obes Relat Dis. 2010;6(3):249–53.
doi: 10.1016/j.soard.2009.09.019
pubmed: 20510288
Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass [J]. Surg Obes Relat Dis. 2010;6(3):254–9.
doi: 10.1016/j.soard.2009.11.003
pubmed: 20303324
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic [J]. Nature. 2001;414(6865):782–7.
doi: 10.1038/414782a
Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes [J]. Ann Surg. 2010;252(6):966–71.
doi: 10.1097/SLA.0b013e3181efc49a
pubmed: 21107106
Rosenthal R, Li X, Samuel S, et al. Effect of sleeve gastrectomy on patients with diabetes mellitus [J]. Surg Obes Relat Dis. 2009;5(4):429–34.
doi: 10.1016/j.soard.2008.11.006
pubmed: 19342307
Hall TC, Pellen MG, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity [J]. Obes Surg. 2010;20(9):1245–50.
doi: 10.1007/s11695-010-0198-8
pubmed: 20524158
Aarts EO. Janssen, et al. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery [J]. Obes Surg. 2013;23(7):867–73.
doi: 10.1007/s11695-013-0872-8
pubmed: 23475775
Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion [J]. Surgery. 2010;147(5):664–9.
doi: 10.1016/j.surg.2009.10.059
pubmed: 20004451
Huang CK, Asim S, Chi-Hsien L, et al. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25–35 [J]. Obes Surg. 2011;21(9):1344–9.
doi: 10.1007/s11695-011-0408-z
pubmed: 21479764
pmcid: 3157602
Sjöström ML, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events [J]. Jama. 2012;307(1):56–65.
doi: 10.1001/jama.2011.1914
pubmed: 22215166
Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score [J]. Surg Obes Relat Dis. 2013;9(3):379–84.
doi: 10.1016/j.soard.2012.07.015
pubmed: 22963817
National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998 Sep;6 Suppl 2:51S–209S